Penumbra's THUNDERBOLT Receives FDA Clearance for Stroke Treatment
PEN sits 44% above its 52-week low of $221.26.
Summary
Penumbra has secured FDA clearance for its THUNDERBOLT system, bringing computer-assisted vacuum thrombectomy (CAVT) technology to acute ischemic stroke treatment. This is the first CAVT platform to offer modulated aspiration for stroke, aiming for faster and more complete clot removal. The company highlights THUNDERBOLT as the only CAVT device available for stroke in the U.S., positioning it as a significant advancement in patient care and a potential driver for future growth in a critical medical area.
At the time of this announcement, PEN was trading at $318.32 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $221.26 to $362.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.